If you run a 340B program at an FQHC, you already know the landscape shifts every quarter. Here is what changed heading into the second half of 2025 and what it means for your operations.
HRSA Tightened the Registration Window
Starting in May 2025, HRSA shortened the recertification window from 90 days to 60 days. That sounds small until you are the pharmacy director juggling site audits and contract pharmacy renewals at the same time. If you missed the notice buried in the Federal Register, you are not alone. But missing the deadline means your entity drops off the OPAIS database, and your wholesaler stops shipping at ceiling price the next business day.
The fix is straightforward: put the recertification date on your compliance calendar 90 days out, not 60. Give yourself the buffer HRSA just took away.
Contract Pharmacy Integrity Requirements
HRSA finalized new contract pharmacy standards that require covered entities to conduct quarterly utilization reviews of every contract pharmacy arrangement. The agency is specifically looking for three things: whether the contract pharmacy dispenses to a disproportionate share of non-340B-eligible patients, whether duplicate discounts are being adequately prevented, and whether the covered entity maintains meaningful oversight of the arrangement.
For FQHCs with more than five contract pharmacies, this means dedicated staff time every quarter. If you have been relying on your TPA to handle this without independent verification, that approach no longer meets the standard.
Manufacturer Restrictions Keep Expanding
Three more manufacturers imposed contract pharmacy limitations in Q2 2025. The playbook is the same: they require claims-level data submission through a designated third-party administrator before honoring 340B pricing at contract pharmacies. If you are not already submitting claims data to 340B ESP or a similar platform, your contract pharmacy savings on those manufacturers are gone.
The practical impact depends on your formulary mix. Run a report on your top 20 drugs by 340B savings and cross-reference against the restricted manufacturer list. If more than 30 percent of your savings come from restricted manufacturers, you need an in-house pharmacy strategy, not just a contract pharmacy network.
Mixed-Use Inventory Changes
HRSA clarified its position on virtual inventory models for mixed-use settings. Covered entities using the replenishment model must now document the replenishment transaction within 7 business days of the original dispense, down from the informal 14-day window many programs were operating under. The accumulator model remains unchanged, but HRSA signaled in its June guidance letter that it plans to revisit accumulator thresholds later this year.
If your pharmacy uses replenishment, update your standard operating procedures now. A 7-day turnaround is tight when your wholesaler delivers twice a week.
What This Means for Your Program
None of these changes are catastrophic on their own. But stacked together, they add compliance burden at a time when pharmacy teams are already stretched thin. The organizations that handle this well are the ones that treat 340B compliance as an ongoing operational function, not an annual audit exercise.
If your last policy review was more than six months ago, it is time.
Stay Ahead of These Changes
Keeping up with 340B program changes is operational work — but responding to them is strategic. We build tools that turn regulatory complexity into actionable intelligence:
HRSA OSV Readiness Assistant — Scores your audit readiness across every compliance domain before HRSA arrives.
Compliance Command — One dashboard for every compliance requirement across multiple sites and regulatory authorities.
See all 13 prototypes live → quantum5d.ai
Need help interpreting how these changes affect your program? Let's talk →